Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Methotrexate monotherapy: Methotrexate monotherapy in group A (25 patients) of moderate to severe psoriasis vulgaris and documenting the hsCRP level in blood before and after interventi
Sponsors
Saveetha Medical College
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with both psoriasis vulgaris and metabolic syndrome between the ages of 18 and 70 years consenting to be a part of the study 2. Patients with chronic plaque psoriasis 3. Patients with active disease 4. Patients who are currently not on any systemic treatment 5. Patients are nonalcoholic; liver and kidney function tests are normal
Exclusion criteria
Exclusion criteria: 1. Patients not willing to be a part of the study 2. Patients not consenting for biopsy or blood test 3. Patients diagnosed with conditions other than psoriasis 4. Patient is pregnant or lactating 5. Patient has been using systemic drugs to treat psoriasis—such as cyclosporine, retinoid, or immunologic therapy—for one month or more 6. Patient has acute or chronic infection 7. Contraindication to use metformin and methotrexate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of the Methotrexate monotherapy compared to Methotrexate-Metformin combination therapy in reducing hsCRP levels in patients with moderate to severe psoriasisTimepoint: 0 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of hsCRP, QRISK3 Caridovascular risk score and Ki67 percentage in moderate to severe psoriasis patientsTimepoint: 0 and 12 weeks | — |
Countries
India
Contacts
Public ContactANANNYA S
Saveetha Medical College
Outcome results
None listed